Interviews with leading Life Sciences companies: FerroptoCure

This FerroptoCure interview explores how the Tokyo-based biotechnology company is developing orally administered small-molecule cancer therapies designed to induce ferroptosis, an iron-dependent form of non-apoptotic cell death. Its therapeutic approach targets xCT and ALDH, two components of the antioxidant defense system that helps cancer cells withstand oxidative stress.

The company’s lead program, FC-001, is progressing through a Phase I first-in-human clinical trial for patients with advanced or recurrent solid tumors refractory to standard therapies. FerroptoCure’s initial focus includes triple-negative breast cancer, a difficult-to-treat form of breast cancer with limited targeted treatment options. The company is also exploring FC-001’s potential across other solid tumor types, subject to further clinical validation.

In this installment of our Let’s Interview Series, Venture Valuation speaks with Otsuki Yuji, MD, PhD, CEO and Co-founder of FerroptoCure. The interview covers the science behind ferroptosis, the company’s clinical pipeline, its global development strategy, and its interest in strategic partnerships.

Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?